TREE NEWS update: Merck on September 16 launched a new tablet formulation of PREVYMIS (letermovir) in China. The non-nucleoside CMV inhibitor is indicated for prophylaxis of cytomegalovirus infection and CMV disease in adult and pediatric (6 months and older, weighing at least 6 kg) allogeneic hematopoietic stem cell transplant recipients who are CMV-seropositive [R+].
Merck Launches New Letermovir Tablet Formulation in China for CMV Prevention
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
13m ago
SoftBank shares fall 7.9% after Arm earnings report
17m ago
Citi Sets 0-3 Month Gold Target at $4,500/oz, 6-12 Month at $5,000
26m ago
Nikkei 225 opens up 0.2%, Kospi falls 2%
26m ago
Agricultural Development Bank of China Issues Four Bonds Totaling 80 Billion Yuan
30m ago
JPMorgan Adds Bitcoin to 2027 Long-Term Capital Market Assumptions, Forecasts 10% Annual Return
30m ago
China to issue government and policy financial bonds